EGFR and non-small cell lung carcinoma: Building on the post hoc data from IMpower150, a phase 2 trial named Neo-DIANA (ClinicalTrials.gov: NCT04512430) was launched to evaluate neoadjuvant atezolizumab combined with platinum-based doublet chemotherapy and bevacizumab in EGFR-mutant NSCLC patients.